S&P Futures
4,221.50 +11.50 (+0.27%) Dow Futures
33,356.00 +96.00 (+0.29%) Nasdaq Futures
13,443.25 +51.25 (+0.38%) Russell 2000 Futures
1,975.60 +6.10 (+0.31%) Crude Oil
91.87 -0.06 (-0.07%) Gold
1,801.50 -12.20 (-0.67%)
Endo International plc (ENDP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.4030 |
| Open | 0.4200 |
| Bid | 0.4212 x 3100 |
| Ask | 0.4296 x 2200 |
| Day's Range | 0.3800 - 0.4400 |
| 52 Week Range | 0.2800 - 7.0700 |
| Volume | |
| Avg. Volume | 52,253,754 |
| Market Cap | 101.71M |
| Beta (5Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.1110 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ENDP
Related Research
- Endo International plcENDP: Lowering target price to $0.24ENDO INTERNATIONAL PLC has an Investment Rating of SELL; a target price of $0.240000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat2 months agoArgus Research
- The Wall Street Journal
Drugmaker Endo Says Bankruptcy Likely Imminent
The drugmaker has been in talks with lenders, but also faces thousands of lawsuits from government and private plaintiffs alleging it fueled opioid addiction.
- Benzinga
Endo Shares Plunge On Imminent Bankruptcy Filing
Endo International plc's (NASDAQ: ENDP) Q2 sales decreased 20% to $569.11 million, beating the consensus of $529.94 million. The decrease was attributable to decreased revenues from the Sterile Injectables segment, partially offset by increased revenues from the Generic Pharmaceuticals segment. Sterile Injectables segment revenues fell 58% to $123 million, primarily due to decreased Vasostrict revenues due to lower price and generic competition, channel inventory destocking, and lower overall ma
- Zacks
Endo International (ENDP) Tops Q2 Earnings and Revenue Estimates
Endo (ENDP) delivered earnings and revenue surprises of 118.75% and 9.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
